Stock of the Day

July 31, 2023

Bristol-Myers Squibb (BMY)

$55.85
+$0.06 (+0.1%)
Market Cap: $113.22B

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Bull Case

Here are some ways that investors could benefit from investing in Bristol-Myers Squibb:

  • Bristol-Myers Squibb has recently received multiple upgrades from analysts, with ratings moving from "hold" to "strong-buy," indicating strong confidence in the company's future performance.
  • The stock price is currently at $53.85, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • The company has a solid pipeline of products, including recent advancements in treatments for various cancers and autoimmune diseases, which could drive future revenue growth.
  • Bristol-Myers Squibb has increased its quarterly dividend to $0.62 per share, reflecting a commitment to returning value to shareholders and indicating financial stability.
  • With a market capitalization of $109.22 billion, Bristol-Myers Squibb is a significant player in the pharmaceutical industry, providing a level of stability and reliability for investors.

Bristol-Myers Squibb Bear Case

Investors should be bearish about investing in Bristol-Myers Squibb for these reasons:

  • The stock has recently experienced a decline of 3.8%, which may indicate underlying issues or market concerns that could affect future performance.
  • Analysts have assigned a consensus target price of $57.86, suggesting limited upside potential from the current stock price, which may not attract aggressive investors.
  • The company has a negative net margin of 18.53%, indicating that it is currently spending more than it earns, which could raise concerns about profitability.
  • With a debt-to-equity ratio of 2.83, Bristol-Myers Squibb has a relatively high level of debt compared to its equity, which could pose risks in times of economic downturns.
  • Despite a strong product pipeline, the biopharmaceutical industry is highly competitive, and there is always the risk of new entrants or existing competitors impacting market share.

Recent News